CL — Colgate-Palmolive Company

Near-term sentiment is cautious but not bearish: Q2 2026 Base Business EPS beat consensus, gross margin expanded 140bps YoY to 61.5%, and management raised full-year profit guidance. However, the actual FMP analyst data shows a Hold-leaning consensus (18 buy / 25 hold / 2 sell), GAAP EPS has been distorted by a Q4 2025 loss, and the stock is below its 20-day and 50-day moving averages. The market seems to respect the quality but is not chasing the stock.

Revenue inflected upward over the past year: YoY growth went from -3.0% in Q1 2025 to +4.9% in Q2 2026, with organic sales up 2.4% in Q2 2026 and three straight quarters of organic volume growth. Gross margins are clearly expanding, from roughly 60.1% a year ago to 61.5% in Q2 2026. The operating-income picture is less clean: Q2 2026 operating income fell to $1.016B from $1.080B a year earlier, and operating margin slipped to ~19.0% from ~21.1%, largely because advertising spending jumped 15% YoY. Q4 2025 includes a one-off net loss of -$37M, so the TTM GAAP EPS of $2.56 understates underlying profitability. Free cash flow is strong and accelerating—Q2 2026 operating cash flow rose 12.6% YoY to $995M and FCF was $867M. Overall, this is a stable defensive business with recent positive volume/gross-margin momentum, but operating profit is not yet accelerating in a straight line.

Valuation is roughly fair once you adjust for the one-off Q4 2025 charge. The trailing P/E of 35.8x is misleadingly high because TTM EPS of $2.56 is depressed by that charge. Using the next-FY EPS estimate of $3.87, the forward P/E is about 23.5x, below the 5-year average trailing P/E of 30.94x, though that historical average also benefited from cleaner GAAP earnings. Price-to-sales of 3.46x is slightly below the 5-year average of 3.61x. This is not a cheap stock, but it is not expensive on forward adjusted earnings either—investors are paying a reasonable defensive premium for high ROIC, a 2.28% dividend, and category leadership.

At $90.96, the market is pricing in steady, unexciting growth rather than a major acceleration. If management delivers around $3.87 in forward EPS and holds gross margins near current levels, the stock offers moderate upside toward the high-$90s. If volume growth stalls or input-cost/tariff pressure compresses margins, the forward multiple could revert toward 20x, putting the stock near $77—close to the bottom of its 52-week range. The playbook is patience: the current price already reflects much of the good news, so the risk/reward is balanced rather than skewed strongly upward.

As of 2026-08-27, RSI stood at 47.45, which is neutral—not oversold and not overbought. Price was 0.92% below the 20-day SMA, 1.03% below the 50-day SMA, and 4.09% above the 200-day SMA. That is a short-term pullback within a longer-term uptrend, not a breakdown. The stock is in the upper half of its 52-week range ($74.55-$99.33). For entry timing, there is no urgency; a move closer to the rising 200-day SMA would offer a better risk/reward than buying right here.

• Raw-material and tariff inflation: management has flagged potential second-half cost pressures that could partially offset operating gains.
• North American consumer value-seeking: cautious U.S. retail behavior is creating volume and promotional headwinds.
• Defensive sector appeal: with a beta of 0.33, CL functions as a safe-haven asset during macro volatility and rate uncertainty.
• Global diversification: international markets are roughly 70% of the business, which diversifies growth but adds FX exposure.
• Advertising reinvestment: a 15% YoY increase in ad spending supports top-line momentum but pressures near-term operating margins.

• Q3 2026 earnings scheduled for October 23, 2026—the key test is whether gross-margin expansion holds against rising raw-material costs.
• Continued organic volume growth: if the third consecutive quarter of volume gains becomes a sustained trend, estimates and the stock can move higher.
• Analyst target upgrades: the consensus price target is $97.78, and recent targets average $101.50; a clean beat could push targets higher.

• Input-cost inflation and tariff changes could reverse the recent gross-margin expansion.
• North American volume weakness may force more promotional spending and keep operating margin under pressure.
• GAAP earnings volatility: the Q4 2025 net loss shows that one-off charges can distort headline EPS and the reported P/E.
• Limited valuation cushion: with the stock near $91 and consensus targets around $98, a modest earnings miss could send it lower quickly.
• Insider selling in late August 2026—COO and director sales are not individually alarming but are worth monitoring as a sentiment flag.

Colgate-Palmolive is a high-quality defensive compounder with dominant market share, strong free cash flow, high ROIC, and expanding gross margins. But at $90.96, the stock is fairly valued rather than cheap, and the near-term earnings path is clouded by one-off charges, elevated ad spending, and input-cost uncertainty. It is a reasonable core hold for income and stability, but not a high-conviction buy at this price; a pullback toward the high-$80s or lower would make the risk/reward more attractive.

I applied a 25.5x multiple to the next-FY EPS estimate of $3.87, deliberately below the 5-year average P/E of 30.94x to reflect mid-single-digit growth, modest tariff/input-cost risk, and GAAP earnings noise. That yields $98.61, which is also consistent with a P/S of roughly 3.5x on about $21.4B of forward revenue and sits just below the recent analyst average target of $101.50.